BMY

BMY is a high-cash-flow, low-multiple big-pharma name trading at 15.6x GAAP EPS ($3.46) and ~8.8x the $6.15 non-GAAP EPS management cites in the MD&A — a valuation that already prices in decline. The income case is real: $14.2B of operating cash flow easily covers the $5.04B dividend (~$2.47/share, ~4.6% yield at $54), long-term debt fell 10% to $42.9B, and the company is holding $10.2B in cash. ROE of 38.2% and a 63.8% gross margin look strong, though ROE is flattered by a thin $18.5B equity base against $71.5B of liabilities (3.87x).

The problem is the forward trajectory. Revenue was essentially flat in 2025 (-0.2% to $48.2B) because Growth Portfolio and Eliquis demand only just offset generic erosion across the Legacy Portfolio, and management explicitly guides to 'continued generic erosion within our Legacy Portfolio in 2026 primarily due to Revlimid and Pomalyst in the U.S.' On top of that, the IRA's 'maximum fair price' was set for Eliquis — one of the company's largest products — and the MD&A flags broad governmental pricing pressure (price controls, higher U.S. channel rebates, lower reimbursement). This is a portfolio that has to run hard just to stay flat.